Back to Gene
CXCR4 gene
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Gene

CXCR4 gene

The CXCR4 gene provides instructions for making a receptor protein that regulates cell growth, survival, and migration, particularly in white blood cells.

Normal Function

The CXCR4 gene provides instructions for making a receptor protein that spans the outer membrane of cells, specifically white blood cells and cells in the brain and spinal cord (central nervous system). Receptor proteins have specific sites into which certain other proteins, called ligands, fit like keys into locks. After attachment of its ligand, called SDF-1, the CXCR4 protein turns on (activates) signaling pathways inside the cell. These pathways help regulate cell growth and division (proliferation), the process by which cells mature to carry out specific functions (differentiation), and cell survival. Once signaling is stimulated, the CXCR4 protein is removed from the cell membrane (internalized) and broken down so it can no longer activate the signaling pathways.

The CXCR4 receptor is also involved in the movement (migration) of cells. Cells that have the CXCR4 protein in their membrane are attracted to SDF-1. High levels of this ligand are found in the bone marrow, which helps certain blood cells migrate to and stay in the bone marrow until they are needed elsewhere in the body. Retention of early blood cells known as hematopoietic stem cells in the bone marrow is important to ensure that stem cells are available when needed. White blood cells also remain in the bone marrow until they are needed in the body to fight infection.

Health Conditions Related to Genetic Changes

Waldenström macroglobulinemia

Mutations in the CXCR4 gene are found in approximately 30 percent of people with Waldenström macroglobulinemia. This rare form of blood cancer is characterized by an excess of abnormal white blood cells called lymphoplasmacytic cells in the bone marrow and overproduction of a protein called IgM. These mutations are acquired during a person's lifetime and are present only in the abnormal white blood cells. This type of genetic change, called a somatic mutation, is not inherited. Waldenström macroglobulinemia is thought to result from multiple genetic changes, one of which can be a CXCR4 gene mutation.

CXCR4 gene mutations involved in Waldenström macroglobulinemia lead to production of an abnormally short CXCR4 protein that cannot be internalized, prolonging signaling activated by the protein. This signaling leads to enhanced survival and proliferation of cells containing the abnormal protein, which may contribute to the abundance of lymphoplasmacytic cells characteristic of Waldenström macroglobulinemia.

Other disorders

At least nine mutations in the CXCR4 gene have been found to cause WHIM syndrome, a condition characterized by impaired immune function and recurrent bacterial and viral infections. Several of the mutations that cause WHIM syndrome are also found in individuals with Waldenström macroglobulinemia. However, in WHIM syndrome, the mutations are typically inherited and are found in every cell of the body (known as germline mutations).

As in Waldenström macroglobulinemia, the CXCR4 gene mutations that cause WHIM syndrome impair internalization of the CXCR4 protein. Researchers suggest that white blood cells that have the CXCR4 protein in their membrane longer than usual are abnormally retained in the bone marrow (a condition known as myelokathexis). A lack of these immune cells circulating through the body likely impairs the body's immune reaction to bacteria and viruses, leading to the recurrent infections common in WHIM syndrome.

Frequently Asked Questions

targeted next‑generation sequencing panel that includes CXCR4 is typically used. If a mutation is identified, confirmatory testing with Sanger sequencing may be performed. Testing is usually done on peripheral blood or bone marrow samples.
Standard therapy includes rituximab combined with a proteasome inhibitor or alkylating agent. For patients with CXCR4 mutations, adding a CXCR4 antagonist like plerixafor can improve response rates. Clinical trials are also exploring combination regimens that target both B‑cell receptor signaling and CXCR4 pathways.
The mutation can influence the homing and engraftment of transplanted hematopoietic stem cells, potentially leading to delayed engraftment or graft failure. Some transplant protocols incorporate CXCR4 antagonists to improve stem cell mobilization and engraftment efficiency. Discussing these considerations with the transplant team is essential.
Mutations in CXCR4 can activate the receptor more strongly, leading to increased cell survival and proliferation. This often results in a more aggressive disease course, higher blood protein levels, and may affect how patients respond to certain therapies, such as the drug ibrutinib.
Because CXCR4 is involved in immune cell trafficking, mutations can sometimes lead to mild immune dysfunction. Routine blood counts and immune function tests are recommended, especially if patients develop infections or show abnormal white blood cell counts.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

kontakt@hittavard.se

Ⓒ 2024. Alla rättigheter förbehålls av juxt ab